China's COVID-19 vaccine developer Clover raises $240m in HK IPO

China's COVID-19 vaccine developer Clover raises $240m in HK IPO

05 November, 2021

Clover Biopharmaceuticals

Printed by Unregistered user on Tue, 22 Jul 2025 14:58:29 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

GL Ventures, Temasek co-lead $230m round in China's Clover Biopharmaceuticals

Clover Health to list via $3.7b merger deal with blank-cheque firm Social Capital

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation